Since 26 May 2021, Article 117 of the MDR asks for a notified body opinion (NBOp) to be included in the marketing authorisation applications (MAAs) for medicinal products that are a single integral drug-device combination…
Join now to get access to:
Not sure yet? Read one of our free editorials to see what you’re missing out on!